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Abstract 
Background: In contrast to the complexity found in mammals, only two Bcl-2 family genes have been found in 
Drosophila melanogaster including the pro-cell survival, human Bok-related orthologue, Buffy. The directed expression 
of α-synuclein, the first gene identified to contribute to inherited forms of Parkinson disease (PD), in the dopaminergic 
neurons (DA) of flies has provided a robust and well-studied Drosophila model of PD complete with the loss of neu-
rons and accompanying motor defects. To more fully understand the biological basis of Bcl-2 genes in PD, we altered 
the expression of Buffy in the dopamine producing neurons with and without the expression of α-synuclein, and in the 
developing neuron-rich eye.
Results: To alter the expression of Buffy in the dopaminergic neurons of Drosophila, the Ddc-Gal4 transgene was 
used. The directed expression of Buffy in the dopamine producing neurons resulted in flies with increased climbing 
ability and enhanced survival, while the inhibition of Buffy in the dopaminergic neurons reduced climbing ability over 
time prematurely, similar to the phenotype observed in the α-synuclein-induced Drosophila model of PD. Subse-
quently, the expression of Buffy was altered in the α-synuclein-induced Drosophila model of PD. Analysis revealed that 
Buffy acted to rescue the associated loss of locomotor ability observed in the α-synuclein-induced model of PD, while 
Buffy RNA interference resulted in an enhanced α-synuclein-induced loss of climbing ability. In complementary experi-
ments the overexpression of Buffy in the developing eye suppressed the mild rough eye phenotype that results from 
Gal4 expression and from α-synuclein expression. When Buffy is inhibited the roughened eye phenotype is enhanced.
Conclusions: The inhibition of Buffy in DA neurons produces a novel model of PD in Drosophila. The directed expres-
sion of Buffy in DA neurons provide protection and counteracts the α-synuclein-induced Parkinson disease-like pheno-
types. Taken all together this demonstrates a role for Buffy, a Bcl-2 pro-cell survival gene, in neuroprotection.
© 2016 The Author(s). This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Parkinson disease (PD) is the most common human 
movement disorder and the second most common neu-
rodegenerative disease; afflicting about 1–2  % of the 
population over 50  years of age [1, 2]. PD is strongly 
associated with the selective and profound loss of dopa-
minergic (DA) neurons to result in marked clinical fea-
tures which include muscle rigidity, resting tremors, 
postural instability, bradykinesia as well as non-motoric 
symptoms like autonomic, cognitive and psychiatric 
problems [2]. The neuropathological hallmarks exhib-
ited by PD patients include the presence of Lewy Bodies 
(LB) and Lewy Neurites (LN) in surviving neurons. This 
is due to the loss of DA neurons in the substantia nigra 
pars compacta (SNpc) region of the brain, coupled with 
the presence of eosinophilic, intracytoplasmic proteina-
ceous inclusions comprised of the α-synuclein and ubiq-
uitin proteins, among others [2–4]. This unusual protein 
accumulation is believed to lead to cellular toxicity and, 
eventually, the PD pathogenesis. Other associated patho-
logical mechanisms include aberrant protein aggregation 
and mitochondrial damage [5–7]. Although the majority 
of PD cases are considered to be sporadic, familial forms 
have been documented and much has been discovered 
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through study of the associated gene loci in model organ-
isms [8–10]. PARK1/4 was the first gene associated with 
PD to be identified [3], and it encodes for a small solu-
ble protein of unknown function predominantly found 
in neural tissues [3, 8, 11]. The first Drosophila model 
of PD utilized a human α-synuclein transgene to induce 
the PD-like symptoms [12]. The success of this model 
is its ability to recapitulate features of human PD such 
as (1) age-dependent loss in locomotor function (2) LB-
like inclusions and (3) age-dependent loss of DA neu-
rons; and therefore has found wide use for studying the 
molecular basis of α-synuclein-induced neurodegenera-
tion [12–19]. The utilization of the UAS/GAL4 spatio-
temporal expression system [20], and the availability of 
a plethora of promoters or enhancers of which TH-Gal4, 
elav-Gal4 and Ddc-Gal4 are employed in modelling PD 
in flies, makes Drosophila a powerful model organism 
[12–19]. Mitochondrial dysfunction due to the accu-
mulation of α-synuclein has been implicated as one of 
the mechanisms leading to PD [21–24]. The association 
of α-synuclein with components of the mitochondria is 
thought to lead to oxidative stress, apoptosis, autophagy 
and the eventual neurodegeneration.
The Bcl-2 family of genes are key regulators of cell death 
and survival in animals and are functionally composed 
of proapoptotic and pro-cell survival (antiapoptotic) 
members [25–28]. The pro-survival proteins protect the 
mitochondria in part, from disruption by the proapop-
totic proteins [26, 29–32]. In mammals, the antiapoptotic 
members possess four Bcl-2 homology (BH) domains—
BH1, BH2, BH3 and BH4—and include Bcl-2, BclXL, 
Mcl-1 among others. The proapoptotic members, Bax, 
Bak and Bok, have three BH domains: BH1, BH2 and 
BH3. A BH3-only domain class of proapoptotic proteins 
is present and includes Bid, Bim, Bad, Bik, Hrk, Noxa and 
Puma [33–35]. The multi-domain proapoptotic proteins 
are required for mitochondrial outer membrane (MOM) 
permeabilization and the subsequent release of apopto-
genic factors into the cytosol [36–39]. As thus, the antia-
poptotic members guard the mitochondria and stop the 
release of a plethora of death causing molecules that ini-
tiate apoptosis.
The Bcl-2 family of proteins are thought to be the 
“guardians” of the mitochondria, involved in the life 
and death decisions at the cellular level by initiating 
mitochondrial remodelling, mitochondrial outer mem-
brane permeabilization and the release of apoptotic fac-
tors from the mitochondria [40]. This delicate balance is 
maintained by the activity of the pro-survival and anti-
survival members of the protein family. Many of the 
apoptotic pathway proteins that participate in the intrin-
sic and extrinsic cell death pathways have been identi-
fied in Drosophila [41–43]. The Bcl-2 family member 
homologues in Drosophila are limited to the single pro-
cell survival Buffy and the sole pro-cell death Debcl [44–
48]. These two proteins share a strong similarity within 
their domains and with the mammalian pore-forming 
proapoptotic member Bok/Mtd.
In previous studies, the overexpression of Buffy has 
been shown to suppress Pink1 mutant phenotypes [49] 
and suggest a role for this protein (1) in interacting with 
the Pink1 protein and other mitochondrial proteins or (2) 
in a pathway that regulates mitochondrial function and 
integrity. Studies show that Buffy has little involvement in 
cell death during development [50], though it has a role 
in regulating cell death that occurs in response to exter-
nal stimuli and a role in the mitochondrial pathway for 
the activation of cell death during Drosophila oogenesis 
[51], all which point to an important role for this protein 
in aspects of cell death. Indeed, early studies have dem-
onstrated that Buffy plays roles in both anti- and pro-sur-
vival [52, 53] depending upon the stimuli.
A direct role for the Bcl-2 proteins in mitochondrial 
dynamics has been shown in the activation of cell death 
in Drosophila melanogaster during mid-oogenesis [51] 
and in the Pink1 loss-of-function Parkinson disease 
model [49]. The predicted role of the mitochondria in 
PD pathogenesis makes the α-synuclein-induced model 
of PD [12] a very attractive model for the investigation of 
the role of Bcl-2 proteins. First we examine the effects of 
increasing and decreasing Buffy activity in DA neurons 
and, secondly, we investigate the potential suppression of 
the α-synuclein-induced PD phenotypes by the overex-
pression of the pro-survival Bcl-2 homologue Buffy.
Results
Buffy is similar to the human proapoptotic Bok
Bioinformatic analysis of the protein sequences encoded 
by the Buffy and Bok genes reveal 33  % identity. The 
Buffy protein consists of 299 amino acids and reveals the 
presence of the BH1, BH2, BH3, BH4 and TM domains 
(Fig.  1). The Eukaryotic Linear Motif (ELM) resource 
search for functional sites indicates the presence of a 
monopartite variant of a basically charged NLS between 
amino acids 101 and 106. There is a number of BH3-
homology region binding sites in the central region of 
the protein. Bok has 212 amino acids and similarly shows 
the presence of the BH1, BH2, BH3, and BH4 domains. 
Although, the two proteins are determined to be antia-
poptotic and proapoptotic respectively, both show the 
presence of a BH4 domain, the homology domain that is 
associated with pro-survival proteins.
Loss of Buffy decreases lifespan and climbing ability
When Buffy is inhibited in the DA neurons by RNA inter-
ference, the resulting flies have a shortened lifespan and 
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impaired climbing ability. The median lifespan for these 
flies is 58  days compared to 64  days for the controls 
(Fig.  2a). The nonlinear fitting of the climbing curves 
resulted in a slope gradient that was significantly differ-
ent at 95  % confidence interval (Fig.  2b). This suggests 
that Buffy is required for the normal functioning of DA 
neurons and inhibition in DA neurons confers a disad-
vantage by reducing lifespan and impairing the locomo-
tor ability of these flies.
Buffy increases lifespan and climbing ability 
when overexpressed in DA neurons
When Buffy is overexpressed in DA neurons, the sur-
vival parameters of these flies differ slightly (Fig. 2a), with 
Buffy-overexpressing flies having a median lifespan of 
68 days compared to 64 days for the controls. The over-
expression of Buffy in DA neurons led to an increased 
climbing ability as indicated by the nonlinear fitting of 
the curve with 95 % CI (Fig. 2b). This suggests that Buffy 
improves longevity and markedly improves climbing 
ability in Drosophila when expressed in DA neurons to 
improve the general healthspan of these flies.
Inhibition of Buffy enhances the α‑synuclein‑induced 
phenotypes
The inhibition of Buffy by RNA interference when 
co-expressed with α-synuclein, under the directions 
of Ddc-Gal4, results in short-lived flies with strongly 
impaired locomotor function. The median lifespan of the 
α-synuclein-expressing control flies was 60  days, while 
that of those co-expressing the Buffy-RNAi inhibitory 
transgene along with α-synuclein was 50  days (Fig.  3a). 
The climbing ability of these flies was more impaired 
than those expressing α-synuclein alone, as indicated by 
the nonlinear fitting of the climbing curves (Fig. 3b).
Overexpression of Buffy in DA neurons rescues the 
α‑synuclein‑induced loss of climbing ability
The overexpression of Buffy in DA neurons express-
ing α-synuclein results in an increased median lifespan 
of 68  days, compared to 60  days for the control flies 
(Fig.  3a). The climbing curves indicate that there was 
a significant improvement in the climbing ability of the 
flies when Buffy was overexpressed (Fig.  3b) and thus, 
suppressing the phenotypes observed when α-synuclein 
Fig. 1 Buffy is closely related to human Bcl-2 ovarian killer (Bok). When Buffy protein is aligned with human Bok, the Bcl-2 homology (BH) domains 
show strong conservation. Clustal Omega multiple sequence alignment [64, 65] of Drosophila melanogaster Buffy protein (Drosophila melanogaster 
NP_523702.1) with the human Bok (Homo sapiens NP_115904.1) showing the highlighted conserved BH domains, the BH3-homology region 
binding site, and the TM (trans-membrane) helices. Buffy possesses a monopartite basically charged nuclear localisation signal (NLS) region. The 
domains were identified using NCBI Conserved Domain Database Search (CDD) [66]. “Asterisks” indicate the residues that are identical, “colon” 
indicate the conserved substitutions, “dot” indicate the semi-conserved substitutions. Colours show the chemical nature of amino acids: red is small 
hydrophobic (including aromatic), blue is acidic, magenta is basic, and green is basic with hydroxyl or amine groups
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is expressed in DA neurons. This suggests that the over-
expression of Buffy confers protection to DA neurons, as 
a result of the expression of α-synuclein.
Overexpression of Buffy suppresses the 
α‑synuclein‑induced developmental defects in the eye
The expression of α-synuclein in the developing eye 
results in developmental defects. When Buffy is over-
expressed in the developing eye, developmental defects 
resulting from GMR-Gal4 (Fig.  4b, I) and from GMR-
Gal4 and α-synuclein expression (Fig.  4b, IV) are sup-
pressed. The disruption of the ommatidial array is 
restored to control levels in both cases (Fig.  4b). These 
results suggest that overexpression of Buffy is able to 
counteract the toxic effects of α-synuclein in the develop-
ing eye in addition to the effects of GMR-Gal4.
Discussion
The recapitulation of PD-like symptoms in Drosophila 
melanogaster and especially the age-dependent loss of 
climbing ability led to the investigation of gene prod-
ucts that could suppress this phenotype [12, 13, 54]. 
Mitochondrial dysfunction as a result of α-synuclein 
accumulation has been implicated in PD pathogenesis 
and, thus, we have investigated the consequences of 
the overexpression of the Drosophila Bcl-2 homologue 
Buffy. The analysis of climbing over the lifespan of the 
flies has been applied to determine the role of the vari-
ous gene products in rescuing the α-synuclein-induced 
phenotypes [12, 54–56]. This assay allows for scoring of 










































Fig. 2 Buffy alters lifespan and climbing ability when mis-expressed 
in DA neurons. a Directed expression of UAS-Buffy in the DA neurons 
driven by Ddc-Gal4 results in increased survival compared to the con-
trols overexpressing UAS-lacZ, while inhibition via Buffy-RNAi results 
in reduced survival. The genotypes are UAS-lacZ/Ddc-Gal4; UAS-Buffy/
Ddc-Gal4; and UAS-Buffy-RNAi/Ddc-Gal4. Longevity is shown as 
percent survival (P < 0.01, determined by log-rank and n ≥ 200). b 
Directed expression of UAS-Buffy results in increased climbing abil-
ity as determined by non-linear fitting of the climbing curves and 
comparing at 95 % confidence intervals. Inhibition by Buffy-RNAi 
decreased the locomotor ability when expressed in dopaminergic 
neurons. The genotypes are UAS-lacZ/Ddc-Gal4; UAS-Buffy/Ddc-Gal4; 
and UAS-Buffy-RNAi/Ddc-Gal4. Error bars indicate the standard error of 










































Fig. 3 Buffy rescues the α-synuclein-induced phenotypes of 
decreased lifespan and climbing ability. a Directed overexpression of 
Buffy in the DA neurons increase longevity whereas flies with Buffy 
loss-of-function show a decline in lifespan. Genotypes are UAS-α-
synuclein, Ddc-Gal4/UAS-lacZ; UAS-α-synuclein, Ddc-Gal4/UAS-Buffy; 
and UAS-α-synuclein, Ddc-Gal4/UAS-Buffy-RNAi. Longevity is shown 
as percent survival (P < 0.01, determined by log-rank and n ≥ 200). b 
The co-expression of Buffy in the α-synuclein model of PD rescued the 
age-dependent loss in climbing ability. The directed overexpression 
of Buffy in the DA neurons remarkably increased the climbing ability 
over time compared to the control, while the suppression of Buffy 
resulted in flies that climbed similar to the control. The genotypes 
are UAS-α-synuclein; Ddc-Gal4/UAS-lacZ, UAS-α-synuclein; Ddc-Gal4/
UAS-Buffy, and UAS-α-synuclein; Ddc-Gal4/UAS-Buffy-RNAi. Analysis of 
the climbing curves and significance was determined by comparing 
the 95 % confidence intervals. Error bars indicate the SEM, asterisks 
represents statistically significant result and n = 50
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indicator of the effect the overexpressed gene has on the 
phenotype.
The α-synuclein-expressing models of PD in Drosoph-
ila show little difference in lifespan between the control 
and wild type, A53T and A30P α-synuclein flies [12]. In 
our study, when Buffy is overexpressed in the DA neu-
rons under the control of the Ddc-Gal4 driver, there is a 
significant increase in their longevity. This may be partly 
due to defects in mitochondrial complex I function, the 
pro-survival Buffy likely plays a mitochondrial protective 
role to increase longevity. The inhibition of Buffy in the 
DA neurons resulted in a marked decrease in survival. 
This inhibition of Buffy is sufficient to negate its protec-
tive role and thus promote cell death as has recently been 
Fig. 4 Buffy suppresses the α-synuclein-induced developmental defects in the eye. a Scanning electron micrographs when Buffy is overexpressed 
or inhibited in the eye with the eye-specific GMR-Gal4 transgene; (I) GMR-Gal4/UAS-lacZ; (II) GMR-Gal4/UAS-Buffy; (III) GMR-Gal4/UAS-Buffy-RNAi and 
when co-expressed with α-synuclein; (IV) UAS-α-synuclein; GMR-Gal4/UAS-lacZ; (V) UAS-α-synuclein; GMR-Gal4/UAS-Buffy; and (VI) UAS-α-synuclein; 
GMR-Gal4/UAS-Buffy-RNAi. b Biometric analysis showed a significant difference in the disrupted area of the eye when Buffy was inhibited in the 
developing eye (I–III). Biometric analysis shows a marked difference when Buffy is inhibited in an α-synuclein expressing background (IV–VI) with 
decreased ommatidia number and highly degenerated ommatidial array whereas when Buffy is overexpressed in the α-synuclein background, there 
is a rescue of the α-synuclein-induced phenotypes as determined by one-way ANOVA and Dunnett’s multiple comparison test (P < 0.05 and 95 % 
CI), error bars indicate the SEM, asterisks represents statistically significant result and n = 10
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shown by Clavier and colleagues [57]. Thus, the pro-sur-
vival properties of Buffy are evident.
Locomotor dysfunction is one of the associated symp-
toms of PD, the α-synuclein-expressing model demon-
strated a clear age-dependent loss in climbing ability [12]. 
When we overexpressed Buffy in the DA neurons under the 
control of Ddc-Gal4, the flies produced a climbing index 
significantly different from that of control flies. The Buffy 
flies lost the climbing ability later than the control flies and 
is likely due to the protective role that Buffy confers to the 
mitochondria. In contrast, the inhibition of Buffy results in 
a highly compromised climbing ability when compared to 
the controls. The degree of locomotor dysfunction seemed 
to be similar to that observed when α-synuclein is overex-
pressed in DA neurons. Taken together, these results would 
indicate an early protective role for Buffy in the DA neu-
rons even in the absence of induced cellular stress.
The inhibition of Buffy in the DA neurons of the 
α-synuclein-induced PD model significantly decreased 
lifespan, indicating that low levels of Buffy compromise 
the health of DA neurons. When Buffy was overexpressed 
along with α-synuclein, there was a marked improvement 
in the climbing ability of these flies. These results suggest 
that overexpressing Buffy in the DA neurons counteracts 
the α-synuclein-induced phenotype of locomotor dys-
function over their lifespan. The Buffy loss-of-function 
flies displayed a reduced climbing ability compared to 
the control flies. Therefore, expression of the pro-survival 
Buffy can rescue the α-synuclein-dependent model of PD 
from climbing dysfunction.
Directed overexpression of Buffy in the developing eye 
rescues the roughened eye phenotypes caused by Gal4 
and α-synuclein expression, whereas the inhibition of 
Buffy results in a more disrupted ommatidial array. This 
indicates that elevated levels of Buffy in the developing 
eye offers protection from toxic protein insults to normal-
ize cellular differentiation, neurogenesis and cell survival.
Conclusions
Buffy inhibition results in shortened lifespan and 
impaired locomotor function and represents a novel 
model of PD in Drosophila melanogaster. The overex-
pression of Buffy improves healthspan and counteracts 
the effects of α-synuclein expression to demonstrate 
its protective function. Further studies are required to 
fully elucidate how Buffy may interact with the other PD 
genes, and how these interactions fit into the regulation 
of mitochondrial integrity by the Bcl-2 proteins.
Methods
Drosophila media and culture
Stocks and crosses were maintained on a standard 
medium containing cornmeal, molasses, yeast, agar, 
water and treated with propionic acid and methylpara-
ben. Seven millilitre aliquots of media was poured into 
vials, allowed to solidify, and refrigerated at 4–6  °C. 
Stocks were maintained on solid media for two to 
3  weeks before transfer onto new media to re-culture. 
Stocks were kept at room temperature (22 ± 2 °C) while 
crosses and experiments were carried out at 25 and 
29 °C.
Drosophila stocks and derivative lines
UAS-Buffy [52] was generously provided by Dr. Leo-
nie Quinn (University of Melbourne), UAS-α-synuclein 
[12] was provided by Dr. M. Feany of Harvard Medi-
cal School and Dr. J. Hirsch (University of Virginia) 
provided Ddc-Gal4 flies [58]. UAS-Buffy-RNAi (w[*]; 
P{w[+mC]  =  UAS-Buffy.RNAi}3), GMR-Gal4 [59] and 
UAS-lacZ flies were obtained from the Bloomington 
Drosophila Stock Center at Indiana University. The UAS-
α-synuclein/CyO; Ddc-Gal4/TM3 was generated using 
standard homologous recombination methods and was 
used to overexpress α-synuclein in the dopaminergic 
neurons using the dopa decarboxylase (Ddc) transgene. 
The UAS-α-synuclein/CyO; GMR-Gal4 line was used to 
overexpress α-synuclein in the developing eye using the 
Glass Multiple Reporter (GMR) elements. PCR reactions 
and gel electrophoresis were used for analysis of recom-
bination events.
Ageing assay
Several single vial matings of five females and three males 
of each genotype were made and a cohort of critical class 
male flies were collected upon eclosion. At least two hun-
dred flies were aged per genotype at a density of ≤20 
flies per vial on fresh media which was replenished every 
other day to avoid crowding. Flies were observed and 
scored every 2 days for the presence of deceased adults. 
Flies were considered dead when they did not display any 
movement upon agitation [60]. Longevity data was ana-
lysed using the GraphPad Prism version 5.04 and survival 
curves were compared using the log-rank (Mantel-Cox) 
test. Significance was determined at 95 %, at a P value less 
than or equal to 0.05 with Bonferroni correction.
Climbing assay
A cohort of critical class male flies was collected upon 
eclosion and scored for their ability to climb over their 
lifetime [56, 61]. Every 7 days, 50 males from every geno-
type were assayed for their ability to climb 10 cm in 10 s 
in a clean climbing apparatus in ten repetitions. Analysis 
was performed using the GraphPad Prism version 5.04 
and climbing curves were fitted using non-linear regres-
sion and compared using 95 % confidence interval with a 
0.05 P value.
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Scanning electron microscopy of the Drosophila eye
Several single vial matings were made at 29  °C and a 
cohort of adult male flies collected upon eclosion and 
aged for 3 days before being frozen at −80 °C. Whole flies 
were mounted on scanning electron microscope stubs, 
desiccated overnight and photographed with a FEI Min-
eral Liberation Analyzer 650F scanning electron micro-
scope. For each cross at least 10 eye images were analysed 
using the National Institutes of Health (NIH) ImageJ 
software [62] and biometric analysis performed using 
GraphPad Prism version 5.04. The percent area of eye 
disruption was calculated as previously described [63].
Abbreviations
BH: Bcl-2 homology; Bcl-2: B cell lymphoma 2; DA: dopaminergic; Ddc: dopa 
decarboxylase; PD: Parkinson disease; RNAi: ribonucleic acid interference; SEM: 
standard error of the mean.
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